VENLO, THE NETHERLANDS--(Marketwire - December 03, 2007) - Assay development centre for Singapore will support QIAGEN’s global leadership expansion in the market for molecular testing solutions VENLO, The Netherlands / SINGAPORE, December 3, 2007 - QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA), a leading provider of sample and assay technologies, and Bio*One Capital, one of the largest dedicated biomedical investment management companies in Asia, today announced that they have entered into a joint venture to establish Dx Assays Pte Ltd (“Dx Assays”). Dx Assays expects to be one of the first centres in Singapore for assay development in which molecular diagnostics for infectious and genetic diseases will be developed. The centre is expected to be fully operational by early 2008, employ more than 30 scientists and be equipped with state-of-the-art technology.
